Tg Therapeutics earnings were $461.9M for the trailing 12 months ending Mar 31, 2026, with 1,092.6% growth year over year. The latest TGTX earnings report on Mar 31, 2026 announced Q1 2026 earnings of $19.8M, down 14.2% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, TGTX reported annual earnings of $447.2M, with 1,812.4% growth. The next TGTX earnings date is Aug 3, 2026.
TGTX past earnings growth
How has TGTX's earnings growth performed historically?
What were Tg Therapeutics's earnings last quarter?
Tg Therapeutics (NASDAQ: TGTX) reported Q1 2026 earnings per share (EPS) of $0.14, up 366.67% year over year. Total TGTX earnings for the quarter were $19.78 million. In the same quarter last year, Tg Therapeutics's earnings per share (EPS) was $0.03.
The next TGTX earnings call is Aug 3, 2026. Add TGTX to your watchlist to be reminded of Tg Therapeutics's next earnings date.
Is Tg Therapeutics profitable or losing money?
As of the last Tg Therapeutics earnings report, Tg Therapeutics is currently profitable. Tg Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was $461.90 million, a 1,079.81% increase year over year.
What was TGTX's earnings growth in the past year?
As of Tg Therapeutics's earnings date in Q3 2026, Tg Therapeutics's earnings has grown 1,092.59% year over year. This is 1,041.93 percentage points higher than the US Biotechnology industry earnings growth rate of 50.66%. TGTX earnings in the past year totalled $461.90 million.
What are Tg Therapeutics's earnings expectations?
The current EPS estimate for Tg Therapeutics's earnings report in Aug 3, 2026 is $0.44.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.